OneMedForum NY 2011 welcomes MEDomics, LLC, a molecular diagnostic laboratory, confirmed to present in June at the annual conference. The company provides support to physicians in delivering medicine based on analysis of the patient’s genome. Its services include co- experimental design and wet bench, bioinformatics, post-bioinformatics interpretation, and manuscript co-preparation services. The company also provides diagnosis of mitochondrial diseases. It serves academia, pharmaceutical discovery and development, and veterinary medicine sectors.
Medomics has received an investment of an undisclosed amount from SpaGus Ventures to “fuel the continued growth” of its sequencing-based tests for mitochondrial disease diagnosis, the company said this week.The financing marks SpaGus’ second investment in privately held Medomics.
Additionally, Medomics has hired SpaGus president, Gary Augusta, as chief operating officer. Augusta will also join the Medomics Board and lead the company’s corporate development initiatives.
Medomics currently has two next-gen sequencing based diagnostic tests on the market — MitoDx and MitoNucleomeDx — both of which are based on Life Technologies’ SOLiD system. According to the company, its tests “have produced over $2 million in sales over a few months of limited release in the market.”